Bradley Campbell, President and COO of Amicus Therapeutics, was recently interviewed for Site Selection Magazine, sharing insight on the Company’s strategic decision to select emerging medical hub, Philadelphia, as choice city and new home of Amicus’ state-of-the-art Global Research and Gene Therapy Center of Excellence.
Investors & Media ❯ Featured Coverage
Click Below to Sort Topics
Amicus Therapeutics wins the UK Prix Galien award for Innovative Product, marking the first time in the history of the awards that an orphan drug received this esteemed recognition.
Amicus Therapeutics and Dr. James Wilson with the UPenn Gene Therapy Program are awarded Deal of the Year for their collaboration to advance AAV gene therapy research for rare metabolic disorders.